Dr Reddy's Laboratories jumps into the fray for Biogen's biosimilars

Dr Reddy's Laboratories (DRL) and Intas Pharmaceuticals, both Indian companies, are reportedly in the race to acquire the biosimilar products portfolio of Biogen, a US-based biotech company. Samsung Bioepis is also said to be a candidate for the acquisition. Biogen had sold off its stake in Samsung Bioepis last year. DRL has been aggressively expanding its biosimilars portfolio globally and has launched several products in India and emerging markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/69Psnb2
via IFTTT